biotech / news / / The Manila Times
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
The Phase III OptiTROP-Breast03 trial of sac-TMT met its primary endpoint of PFS in first-line TNBC.
KEY POINTS
- Sac-TMT showed statistically significant and clinically meaningful PFS improvement over chemotherapy in TNBC.
- No new safety signals were observed for sac-TMT in this first-line TNBC Phase III trial.
- Kelun-Biotech will now discuss the regulatory pathway with Chinese authorities based on these results.
- Sac-TMT is the world's first TROP2 ADC approved for lung cancer and now has four indications in China.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →